AtG
AtG Therapeutics, a pre-clinical stage biotech focused on stopping cancer metabolic adaptation, has announced the appointment of Itziar Canamasas, PhD as its new CEO. Dr. Canamasas brings over 20 years of experience in the pharmaceutical industry, with expertise focused on global commercialisation, strategic life-cycle development, corporate strategy, and country leadership. She was most recently the […]
La empresa AtG Therapeutics, una “spin-off” surgida del IDIBELL y el Instituto Catalán de Oncología (ICO), ha cerrado una ronda de financiación con la que ha recaudado más de medio millón de euros para desarrollar alternativas terapéuticas para cánceres avanzados y un sistema de cribado para estos pacientes. Read more
AtG Therapeutics is a recently created spin-off from IDIBELL and ICO, announces its launch with a first round of financing collecting 556,000 euros, received the support of international and national entities, including Blue Goose Capital, Women Angels for STEAM (WA4STEAM), the StapleCat/Inveniam group, and renowned international scientists. AtG Therapeutics has been founded by researchers Oriol […]
Oriol Casanovas and Gabriela Jiménez, AtG team, answer to the “Questions for the Future” of La Vanguardia newspaper. A note on the Big Vang section, featuring research projects financed by La Caixa. Find more about the interview on the link.
La Fundación para la Innovación y la Prospectiva en Salud en España (FIPSE), nos ha galardonado con una ayuda para financiar estudios de viabilidad de nuestra innovación, fuimos seleccionado como uno de los mejores proyectos de investigación del sector salud. Esta ayuda nos dotará de nuevas capacidades para desarrollar nuestros productos que generarán un alto […]
Angiotheragnostics have been selected to participate at CRAASH. CRAASH Barcelona is a 12-week program that helps European research teams launch successful device, diagnostic and e/digital health innovations to improve health and patient care. This program is organized by Biocat in collaboration with both CIMIT and EIT Health. It is one of the flagship programs of Moebio, Biocat’s initiative for acceleration and […]
Angiotheragnostics was awarded with a Caixaimpulse Grant. This is the result of hard team work. We hope that all together, with the support from Banco La Caixa, succeed in further developing a new drug to prevent cancer therapeutic resistance together with its patient selection biomarker.
EADA is a Business School located in the heart of Barcelona. Its masters are ranked amongst the top in the world according to The Financial Times and it is accredited by the most reliable agencies, such as EQUIS or AACSB. EADA has developed several business collaborations with private and public agencies. One that has proven […]
AtG has been selected to participate in Bio€quity Europe 2019. Bio€quity 2019, the most important biopharmaceutical investor conference in Europe, took place in Barcelona for the first time on May 20-21, 2019. Organized by BioCentury and EBD Group is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, […]
AtG has been selected to participate in IMAGINE IF! accelerator program from Innovation Forum and supported by Cambridge Squared and Johnson & Johnson Innovation. This is a global competition and accelerator for healthcare in science venture, with tailored mentoring and access to the Innovation Forum professional network from University of Cambridge and University of Oxford, […]